Supply Chain Intelligence

Summit Therapeutics Inc. Supply Chain

SMMT supply chain intelligence for Summit Therapeutics Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

SMMT ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

14Suppliers
8Customers
2Debt Items
20Related Chains

Summit Therapeutics Inc. Suppliers

TickerNameConfidenceEvidence
AKESO AKESO 92% Pursuant to the terms of the License Agreement, Summit has final decision-making authority with respect to all of its commercialization activities including, but not limited to, commercial strategy, …
AKESO-INC AKESO-INC 92% Since in-licensing ivonescimab, from Akeso Inc. (Akeso, HKEX Code: 9926.HK) in January 2023, over 4,000 patients have been treated with ivonescimab in clinical studies globally, and over 70,000 patie…
GSK GSK plc 90% Reciprocal relationship from GSK graph: Reciprocal relationship from SMMT graph: In January 2026, we announced a clinical collaboration with GSK plc (GSK) to evaluate ivonescimab in combination with …
GSK GSK plc 90% In January 2026, we announced a clinical collaboration with GSK plc (GSK) to evaluate ivonescimab in combination with GSK's novel B7-H3, risvutatug rezetecan, in multiple solid tumors.
REVOLUTION-MEDICINES-INC REVOLUTION-MEDICINES-INC 90% In June 2025, we announced a clinical collaboration with Revolution Medicines, Inc. (RevMed) to evaluate ivonescimab in combination with three RAS(ON) inhibitors, including the multi-selective 3 inhi…
GORTEC GORTEC 85% In February 2026, we announced a clinical collaboration with GORTEC, a European Head and Neck Oncology and Radiotherapy Group based in France, to evaluate ivonescimab monotherapy and ivonescimab in c…
BNTX BioNTech SE 72% Reciprocal relationship from BNTX graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from BNTX g…
BNTX BioNTech SE 72% commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia…
CELG-RI CELG-RI 72% Reciprocal relationship from CELG-RI graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in …
CELG-RI CELG-RI 72% commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (…
JNJ Johnson & Johnson 72% commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia…
MRK Merck & Co., Inc. 72% commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia…
MRK Merck & Co., Inc. 72% Reciprocal relationship from MRK graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from MRK graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in the Unit…

Summit Therapeutics Inc. Customers

TickerNameConfidenceEvidence
BNTX BioNTech SE 72% commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia…
BNTX BioNTech SE 72% Reciprocal relationship from BNTX graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions …
CELG-RI CELG-RI 72% commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia…
CELG-RI CELG-RI 72% Reciprocal relationship from CELG-RI graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regio…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (…
JNJ Johnson & Johnson 72% commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia…
MRK Merck & Co., Inc. 72% Reciprocal relationship from MRK graph: Reciprocal relationship from SMMT graph: commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (…
MRK Merck & Co., Inc. 72% commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, Middle East and Africa regions (collectively, the “Licensed Territory”). Akeso retained development and commercia…

Summit Therapeutics Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
SMMT-DEBT-12608 Warrants outstanding: 3358732 90% xbrl warrant detail from xbrl 2025-12-31.
SMMT-DEBT Debt stack $20.0M 90% Market cache reports total debt of $20.0M.

Summit Therapeutics Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Summit Therapeutics Inc..

Summit Therapeutics Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Summit Therapeutics Inc..

Summit Therapeutics Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
BNR Burning Rock Biotech Limited 100.00 2
CSTE Caesarstone Ltd. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 1 ['spend']
BSX Boston Scientific Corporation 100.00 2
PSNL Personalis, Inc. 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
BDRX Biodexa Pharmaceuticals Plc 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
ANIK Anika Therapeutics, Inc. 100.00 2
AUTL Autolus Therapeutics plc 100.00 2
BNRG Brenmiller Energy Ltd 100.00 2
AORT Artivion, Inc. 100.00 2
AVBP ArriVent BioPharma, Inc. 100.00 2
DEO Diageo plc 100.00 2
BNBX BNB Plus Corp. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
BLLN BillionToOne, Inc. 100.00 2
IMMP Immutep Limited 100.00 2
CELG-RI BRISTOL MYERS SQUIBB CO 100.00 1 ['customer', 'supplier']
View SMMT supply chain intel →

Explore the full interactive supply chain map for Summit Therapeutics Inc..

Open SMMT supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map